Menu
Close
Stories & News
Resources
Stay Informed
x
Stay Informed
September 8, 2022
In 2022, Pfizer has put capital to work as we strive to fuel future growth and return cash dividends directly to investors.
In the first six months of 2022, the company re-invested more than $12 billion in total into innovation, consisting of $5.1 billion in its R&D innovation pipeline and more than $7 billion in completed business development transactions.
In addition, $4.5 billion in cash dividends was returned to shareholders by August 2022. On Sept. 6, Pfizer paid a cash dividend of $0.40 per share to investors. See some key dates below.
*Transactions remain subject to certain closing conditions.
Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website.
Copyright © 2002 – 2025 Pfizer Investor Insights All rights reserved. This information—including product information—is intended only for residents of the United States. The products discussed herein may have different labeling in different countries. This website contains certain information about Pfizer, but may not contain all information that is material to Pfizer.